- Report
- March 2024
- 191 Pages
Global
From €3237EUR$3,374USD£2,799GBP
€3597EUR$3,749USD£3,111GBP
- Report
- March 2024
- 189 Pages
Global
From €3237EUR$3,374USD£2,799GBP
€3597EUR$3,749USD£3,111GBP
- Report
- May 2024
- 94 Pages
Global
From €5373EUR$5,600USD£4,646GBP
- Report
- December 2023
- 150 Pages
Global
From €5709EUR$5,950USD£4,937GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- October 2023
- 150 Pages
Global
From €4654EUR$4,850USD£4,024GBP
- Report
- September 2021
- 354 Pages
Global
From €3833EUR$3,995USD£3,315GBP
- Report
- December 2021
- 109 Pages
Global
From €4318EUR$4,500USD£3,734GBP
- Report
- April 2022
- 94 Pages
Global
From €6712EUR$6,995USD£5,804GBP
- Report
- July 2022
- 303 Pages
Global
From €3684EUR$3,840USD£3,186GBP
- Report
- April 2023
- 147 Pages
Global
From €5756EUR$5,999USD£4,977GBP
Mast Cell Stabilizers are a type of respiratory drug used to treat asthma, allergic rhinitis, and other allergic conditions. They work by blocking the release of histamine and other inflammatory substances from mast cells, which are a type of white blood cell. This helps to reduce the symptoms of allergies and asthma, such as sneezing, wheezing, and difficulty breathing. Mast Cell Stabilizers are typically taken orally or inhaled, and are available in both prescription and over-the-counter forms.
Mast Cell Stabilizers are an important part of the respiratory drug market, as they can help to reduce the severity of allergic reactions and asthma symptoms. They are often used in combination with other medications, such as corticosteroids and bronchodilators, to provide more comprehensive relief.
Some companies in the Mast Cell Stabilizer market include GlaxoSmithKline, Merck, Novartis, and Sanofi. Show Less Read more